How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD

@article{Steiner2009HowCW,
  title={How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD},
  author={George Steiner},
  journal={Cardiovascular Drugs and Therapy},
  year={2009},
  volume={23},
  pages={403-408}
}
  • G. Steiner
  • Published 2009
  • Medicine
  • Cardiovascular Drugs and Therapy
PurposeIntensive multifactorial risk factor intervention, targeting blood glucose, blood pressure and low-density lipoprotein cholesterol, is central to therapeutic management of type 2 diabetes. This strategy reduces, but does not eliminate the risk for cardiovascular complications, and microvascular complications such as diabetic retinopathy and nephropathy still continue to develop or progress. Fibrates have been shown to be effective in managing mixed dyslipidemia characterized by elevated… Expand
Cardiovascular disease in diabetes mellitus: risk factors and medical therapy.
TLDR
This review summarizes the current state of knowledge and discusses areas of uncertainty in the care of patients with diabetes who are at risk for cardiovascular disease. Expand
INFLUENCE OF DYSLIPIDEMIA ON SOMATIC NEUROPATHY IN TYPE 2 DIABETES MELLITUS
TLDR
Higher age and duration of diabetes are associated with PNP in type 2 diabetes, and Hypertriglyceridemia is correlated with severity of PNP. Expand
Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
TLDR
Fenofibrate may predispose individuals with high pretreatment HCY towards VTE andHyperhomocysteinemia is prospectively associated with VTE, according to a Cox proportional-hazards model. Expand
Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.
TLDR
Genetic effects that contributed to the variability of lipid responses to fenofibrate may differ in subjects with and without MetS, and this research may provide guidance for more personalized and effective therapies. Expand
Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease.
TLDR
The circulating angiopoietic CPCs, EPCs, and matEPCs in T2DM patients with DR had a different regulations, with increasing relative differences occurring in proliferative DR, apparently depending on the macrovascular comorbidities. Expand
Triglycerides and Amputation Risk in Patients With Diabetes
TLDR
Hypertriglyceridemia is a significant risk factor for LEA in diabetic patients even after controlling for known socioeconomic, health behavioral, and clinical factors and this previously unrecognized clinical risk needs to be further investigated. Expand
Triglycerides and Amputation Risk in PatientsWith Diabetes Ten-year follow-up in the DISTANCE study
RESEARCHDESIGNANDMETHODS—This is a 10-year survey follow-up study (from 1995–2006) of 28,701 diabetic patients with a baseline triglyceride measure. All patients were fully insured members of theExpand
Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?
TLDR
The lowering of plasma 1-deoxySL levels by fenofibrate in dyslipidemic patients might be a novel therapeutic approach in the prevention and treatment of diabetic neuropathy. Expand
Role of the Peroxisome Proliferator Activated Receptors in Hypertension
TLDR
This review of nuclear receptors focuses on the PPAR (peroxisome proliferator-activated receptor) family of adopted orphan receptors paying special attention to PPARγ, the isoform with the most compelling evidence as an important regulator of arterial blood pressure. Expand
The effect of levosimendan on lung damage after myocardial ischemia reperfusion in rats in which experimental diabetes was induced.
TLDR
The results showed that levosimendan had a protective effect against lung damage secondary to IR in the rats with induced diabetes, and it is recommended that experimental and clinical studies be conducted to examine the effects of levosIMendan at different doses and different IR durations on various organs for clinical use. Expand
...
1
2
...

References

SHOWING 1-10 OF 61 REFERENCES
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
TLDR
A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent. Expand
Lipoprotein Management in Patients With Cardiometabolic Risk
TLDR
It is unclear whether lipoprotein parameters other than LDL or non-HDL cholesterol provide clinically significant additional prognostic information regarding CVD risk, yield more information about the effectiveness of therapy, or indicate more appropriate treatment targets. Expand
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study
TLDR
Treatment with fenofibrate reduces the angiographic progression of coronary-artery disease in type 2 diabetes, even those previously judged not to need treatment, according to a computer-assisted quantitative approach. Expand
Effect of a multifactorial intervention on mortality in type 2 diabetes.
TLDR
In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes. Expand
Effects of intensive glucose lowering in type 2 diabetes.
TLDR
The use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events and identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. Expand
Effects of Intensive Glucose Lowering in Type 2 Diabetes
TLDR
The use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events, identifying a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. Expand
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
TLDR
A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy. Expand
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
TLDR
Fenofibrate did not significantly reduce the risk of the primary outcome of coronary events, but it did reduce total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularisations. Expand
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
TLDR
Routine administration of a fixed combination of perindopril and indapamide to patients with type 2 diabetes was well tolerated and reduced the risks of major vascular events, including death, which suggest that over 5 years, one death due to any cause would be averted. Expand
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
TLDR
Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. Expand
...
1
2
3
4
5
...